GlassScriptPhysician profile
Ben W Wilson
NPI 1558364109
$4,037.99
in general payments reported to CMS, 2019-2025
33 companies · $1,044 in 2025
The $1,044 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,018 · 2020: $664 · 2021: $888 · 2022: $309 · 2023: $114 · 2025: $1,044.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $779 · Food and Beverage: $379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $778.97 |
| Food and Beverage | $379.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $986.52 | 2025 | Core |
| Novo Nordisk INC | $391.00 | 2019-2022 | |
| Lilly USA, LLC | $325.24 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $261.87 | 2019-2022 | |
| Abbvie INC. | $228.68 | 2019-2023 | Vraylar |
| Pfizer INC. | $205.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $143.51 | 2020-2021 | |
| Antares Pharma, INC. | $135.70 | 2019-2022 | |
| Amgen INC. | $121.94 | 2019-2023 | Repatha, Otezla |
| Dexcom, INC. | $108.93 | 2021-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.36 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $98.38 | 2019-2021 | |
| Astellas Pharma US INC | $94.41 | 2019-2021 | |
| Abbott Laboratories | $93.34 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $92.74 | 2019-2021 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $75.68 | 2019-2020 | |
| Glaxosmithkline, LLC. | $66.14 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $66.12 | 2019-2021 | |
| Depuy Synthes Sales INC. | $57.22 | 2025 | Na |
| Allergan, INC. | $54.79 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $53.75 | 2019-2020 | |
| Eisai INC. | $46.84 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.84 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $31.38 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $28.62 | 2021-2022 | |
| Esperion Therapeutics, INC. | $17.92 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.23 | 2020 | |
| Shire North American Group INC | $15.72 | 2019 | |
| Exact Sciences Corporation | $14.78 | 2023 | Cologuard Collection Kit |
| Daiichi Sankyo INC. | $14.77 | 2019 | |
| Lundbeck LLC | $14.27 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $13.37 | 2019 | |
| Mannkind Corporation | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ben Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.